REGISTER
Hyperacute Stroke: Advances in Brain Cytoprotection and Clinical Implementation
This article reviews emerging evidence supporting brain cytoprotection initiated in the hyperacute phase of acute ischemic stroke. It discusses findings from the TASTE-2 and TASTE-SL trials of edaravone dexborneol and explores strategies to integrate neuroprotection into prehospital and in-hospital care pathways alongside reperfusion therapy.

Reperfusion therapy for acute ischemic stroke (AIS) has advanced over the past two decades [1], but vascular recanalization does not equate to brain tissue survival. The concept that “time is brain” has become widely accepted [2,3]. Should brain cytoprotection, like reperfusion, be initiated in the hyperacute phase or even in the prehospital setting, in order to maximize the benefits of neurological protection [2,3]? MedJ invited Prof. Yongwei Zhang from the First Affiliated Hospital of Naval Medical University (Shanghai Changhai Hospital) to share his insights on the evidence base and practical pathways for initiating brain cytoprotection in the hyperacute phase.

Expert Profile: Prof. Yongwei Zhang

Chief Physician; Deputy Director, Cerebrovascular Disease Center; Deputy Director, Clinical Research Ward, First Affiliated Hospital of Naval Medical University (Shanghai Changhai Hospital)

  • l Deputy Secretary-General, China Stroke Specialist Alliance
  • l Standing Committee Member and Youth Standing Director, Severe Cerebrovascular Disease Branch, Chinese Stroke Association
  • l Vice Group Leader, Cerebral Artery Stenosis and Occlusion Group, Neurointervention Branch, Chinese Medical Doctor Association
  • l Member, Neurocritical Care Collaboration Group, Neurology Branch, Chinese Medical Association
  • l Core Member, Oriental Consortium of Evaluation and Research in Cerebrovascular Disease (OCEAN Consortium); has coordinated a series of clinical randomized controlled trials, including DIRECT-MT
  • l Editor-in-Chief of “Interventional Therapy for Acute Ischemic Stroke”; has published 97 articles in journals including The New England Journal of Medicine and The Lancet
  • l Recipient of seven science and technology awards, including the First Prize of the Shanghai Science and Technology Progress Award and the First Prize of the PLA Medical Achievement Award

The Hyperacute Window: A Fleeting Golden Opportunity in Stroke Care

The hyperacute phase generally refers to the first few hours after ischemic stroke onset, during which the ischemic penumbra surrounding the infarct core remains potentially salvageable [2,4]. However, penumbral viability is strictly time-dependent. Prof. Yongwei Zhang noted that the hyperacute phase represents a fleeting golden window in stroke management. During this phase, the primary clinical priority is to achieve vascular recanalization as quickly as possible, but restoring blood flow alone is not sufficient to ensure functional recovery of brain tissue. The aim should be comprehensive neurological recovery, with brain cytoprotection initiated in parallel to maximally salvage the ischemic penumbra and fully realize the clinical value of “time is brain” [2,3].

Why Should Brain Cytoprotection Be Initiated in the Hyperacute Phase?

Reperfusion is a double-edged sword: when blood flow is restored, the sudden surge in oxygen supply provides substrate for the generation of large amounts of reactive oxygen species (ROS) and reactive nitrogen species (RNS), triggering so-called “reperfusion injury.” If brain cytoprotection is initiated before reperfusion, leaving the brain tissue in a relatively “protected” state, the expansion of the infarct core may be slowed, more time may be gained for subsequent vessel recanalization, and the impact of reperfusion injury may be mitigated. Animal studies have shown that neuroprotective interventions can slow the conversion of the ischemic penumbra to infarction, a strategy referred to as “freezing” the penumbra [1].

Prof. Yongwei Zhang noted that, over the past two to three decades, global research on neuroprotection has not yielded substantial breakthroughs, as single-target agents have struggled to address the multi-dimensional and multi-phase pathological injury that follows stroke. Encouragingly, recent years have seen major advances in multi-target brain cytoprotection research led by Chinese investigators. Randomized controlled trials have confirmed the clinical efficacy of multi-target agents, marking the transition of brain cytoprotection from basic theory to clinical reality.

Evidence Cornerstone: TASTE-2 Confirms Clinical Benefit of Ultra-Early Initiation

The clinical value of initiating brain cytoprotection in the hyperacute phase was supported by key evidence from the TASTE-2 trial. TASTE-2 [5] is a multicenter, randomized, double-blind, placebo-controlled phase III clinical trial led by Chinese investigators. The study enrolled 1,360 patients with acute ischemic stroke due to large vessel occlusion who were undergoing endovascular thrombectomy.

Edaravone dexborneol was administered before the start of endovascular thrombectomy rather than after vessel recanalization. This design provides an important reference for the timing of brain cytoprotection. If cytoprotection is only initiated after vessel recanalization, brain tissue injury occurring between the onset of ischemia and the completion of recanalization has already taken place, and the potential benefit of any protective strategy will be substantially limited. Initiating cytoprotection earlier, before reperfusion injury occurs, may help establish a protective barrier and limit early expansion of the infarct core.

In TASTE-2, the proportion of patients achieving functional independence at 90 days (mRS 0-2) was 55.0% (379/689) in the edaravone dexborneol group, significantly higher than 49.6% (333/671) in the placebo group (RR=1.11, 95% CI 1.00-1.23, P=0.05). In terms of safety, the incidence of serious adverse events did not differ significantly between the two groups (27.2% vs 25.7%; RR=1.06, 95% CI 0.89-1.26, P=0.53) [5].

A subgroup analysis of TASTE-2 showed that, in patients with clinical-imaging mismatch on admission — that is, those with a clearly identifiable ischemic penumbra — the benefit of ultra-early brain cytoprotection was more pronounced. In this subgroup, the 90-day functional independence rate was 55.5% (178/321) in the edaravone dexborneol group, significantly higher than 42.9% (134/312) in the placebo group (RR=1.29, 95% CI 1.10-1.52, P-interaction=0.003) [5]. These findings suggest that initiating brain cytoprotection before vessel recanalization may help slow infarct core expansion, preserve salvageable brain tissue, and create a more favorable time window for subsequent reperfusion, ultimately translating into meaningful improvement in functional outcomes.

Prof. Yongwei Zhang emphasized that, from the multi-target brain cytoprotection concept proposed in basic research to clinical validation in the TASTE series of randomized controlled trials, current evidence supports the use of multi-target agents to reinforce the benefits of reperfusion therapy and to achieve a synergistic effect between reperfusion and brain cytoprotection. This clinical manifestation of synergy lies at the core value of initiating brain cytoprotection in the hyperacute phase.

From Prehospital to In-Hospital: Embedding Brain Cytoprotection Across the Care Pathway

To further shorten the time from symptom onset to initiation of brain cytoprotection, the treatment window must be extended from the hospital to the prehospital setting. The prehospital phase — from symptom onset to arrival at a stroke center — is the period of most rapid brain tissue injury progression and represents a “treatment vacuum” during which traditional reperfusion therapy has not yet begun. Initiating brain cytoprotection during this phase may help preserve the ischemic penumbra to the greatest extent possible and create a more favorable anatomic and functional foundation for subsequent reperfusion [2].

The TASTE-SL trial [6] reported that, with sublingual edaravone dexborneol, the proportion of patients achieving mRS ≤1 at 90 days reached 64.4%, with a between-group difference of 9.7%. This formulation overcomes the limitations of conventional intravenous preparations, which depend on hospital settings and professional administration; it can be administered in an ambulance or at a primary care site. Sublingual edaravone dexborneol has received Breakthrough Therapy designation from the U.S. Food and Drug Administration (FDA). Its pharmacokinetic profile, characterized by rapid absorption through the sublingual mucosa, may allow cytoprotection to be initiated quickly during emergency transport.

Prof. Yongwei Zhang stated that the ideal model of stroke care should have the following features: the public should possess basic stroke recognition skills, the emergency system should initiate brain cytoprotection in the prehospital phase, in-hospital reperfusion therapy should follow seamlessly upon arrival, and brain cytoprotection and reperfusion should advance in parallel throughout the entire process until the full acute care cycle is complete. Under this model, brain cytoprotection is no longer a “supplement” to reperfusion but a core strategy running in parallel with reperfusion throughout the entire stroke care pathway.

Summary

Stroke care should embed brain cytoprotection across the full care pathway, with rapid prehospital recognition and initiation of protection, and seamless in-hospital transition to reperfusion therapy. This approach not only deepens the practical application of the “time is brain” concept, but also represents a critical step in translating brain cytoprotection from theory into an actionable clinical pathway, with the potential to help more patients achieve functional independence.

References

[1] Chinese Medical Association Neurology Branch, Cerebrovascular Disease Group of Chinese Medical Association Neurology Branch. Chinese Guidelines for the Diagnosis and Treatment of Acute Ischemic Stroke 2023. Chin J Neurol. 2024;57(6):523-559.

[2] Cerebrovascular Disease Group, Neurology Branch, Chinese Medical Doctor Association. Chinese Expert Consensus on the Clinical Evaluation and Treatment of the Ischemic Penumbra in Acute Cerebral Infarction. Chin J Nerv Ment Dis. 2021;47(6):324-335.

[3] Stroke Prevention and Control Expert Committee of the National Health Commission. Guidelines for Prehospital Emergency Diagnosis and Treatment of Stroke. Chin Med J. 2018;98(39):3138-3147.

[4] Chamorro Á, Dirnagl U, Urra X, et al. Neuroprotection in acute stroke: targeting excitotoxicity, oxidative and nitrosative stress, and inflammation. Lancet Neurol. 2016;15(8):869-881.

[5] Wang C, Gu H, Huo X, et al. Edaravone dexborneol versus placebo on functional outcomes in patients with acute ischaemic stroke undergoing endovascular thrombectomy (TASTE-2): randomised controlled trial. BMJ. 2026;392:e086850.

[6] Fu Y, Wang A, Tang R, et al. Sublingual Edaravone Dexborneol for the Treatment of Acute Ischemic Stroke: The TASTE-SL Randomized Clinical Trial. JAMA Neurol. 2024;81(4):319-326.

0
0
Loading